Bimagrumab – Forschung

Efficacy and safety of pharmacological treatments in inclusion body myositis: a systematic review.

Santos EJF, Farisogullari B, Yapp N, Townsley H, Sousa P, Machado PM · RMD Open (2025)

Blocking the activin IIB receptor with bimagrumab (BYM338) increases walking performance: A meta-analysis.

Spitz RW, Dankel SJ, Bell ZW, Wong V, Abe T, Kang M · Geriatr Gerontol Int (2021)

ClinicalTrials.gov identifier: NCT05616013 .

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial

Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM, BELIEVE trial investigators. · Nature medicine (2026)

Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338).

Petricoul O, Nazarian A, Schuehly U, Schramm U, David OJ, Laurent D · Clin Pharmacokinet (2023)

Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial.

Hofbauer LC, Witvrouw R, Varga Z, Shiota N, Cremer M, Tanko LB · Lancet Healthy Longev (2021)

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.

Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O · Neurology (2021)

Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.

Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O · JAMA Netw Open (2021)

Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort.

Rooks D, Petricoul O, Praestgaard J, Bartlett M, Laurent D, Roubenoff R · J Cachexia Sarcopenia Muscle (2020)

Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial.

Rooks D, Swan T, Goswami B, Filosa LA, Bunte O, Panchaud N · JAMA Netw Open (2020)

Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial.

Polkey MI, Praestgaard J, Berwick A, Franssen FME, Singh D, Steiner MC · Am J Respir Crit Care Med (2019)

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H · Lancet Neurol (2019)

Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.

Garito T, Roubenoff R, Hompesch M, Morrow L, Gomez K, Rooks D · Diabetes Obes Metab (2018)

Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes.

Garito T, Zakaria M, Papanicolaou DA, Li Y, Pinot P, Petricoul O · Clin Endocrinol (Oxf) (2018)

Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy.

Rooks DS, Laurent D, Praestgaard J, Rasmussen S, Bartlett M, Tankó LB · J Cachexia Sarcopenia Muscle (2017)

Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study.

Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG · J Am Geriatr Soc (2017)

Treatment of sporadic inclusion body myositis with bimagrumab.

Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J · Neurology (2014)

Future efforts must focus on harmonizing diagnostic criteria, refining therapeutic regimens, and leveraging emerging technologies to develop targeted interventions that preserve muscle function and enhance quality of life in the aging population.

Sarcopenia in Aging: Pathogenesis, Diagnosis, and Emerging Therapeutic Frontiers

Jeyaraman M, Jeyaraman N, Nallakumarasamy A, Ramasubramanian S, Muthu S, Murugan S, Rajendran SNS, Rajendran RL, Ahn BC, Gangadaran P. · Molecular imaging and biology (2026)

Integrating skeletal muscle preservation into obesity management may optimize functional, metabolic, and clinical outcomes, representing a paradigm shift in comprehensive care.

Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives

Lisco G, De Tullio A, Disoteo OE, Dicorato P, Tortora A, De Geronimo V, Triggiani V. · Reviews in endocrine & metabolic disorders (2026)

Preliminary findings are promising, but larger, controlled trials are necessary to confirm efficacy and safety before clinical implementation can be considered.

Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes

Aimelet V, Holst JJ. · Diabetes, obesity & metabolism (2026)

This narrative review discusses the justification for focus on lean mass preservation and reviews the status of relevant drugs in development.

New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?

Ryan DH. · Reviews in endocrine & metabolic disorders (2025)